A Study To Investigate And Describe The Treatment Patterns And Effect Of Tofacitinib Indicators For Patients With Rheumatoid Arthritis

Pfizer

Status: Completed

Conditions: Arthritis, Rheumatoid

Study type: Observational

Funder types: Industry

Identifiers

NCT04721808

A3921379

Details and patient eligibility

About

This study is to investigate and describe the treatment patterns and effect of tofacitinib indicators for patients with Rheumatoid Arthritis (RA) assessing real world patient data entered in the Corrona RA Registry on or after November 2012

Enrollment: 1,712 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Enrolled in the Corrona RA Registry and initiated tofacitinib on or after November 2012
• Initiate tofacitinib (defined as first ever use of tofacitinib) at the Corrona enrollment visit or at a Corrona follow-up visit from November 2012 onward.
• Have CDAI measured at baseline
• Have at least a 6-month follow-up visit and CDAI measured at the 6-month follow-up visit

Exclusion criteria

• There are no exclusion criteria for this study

Trial design

1,712 participants in 1 patient group

Patients with Rheumatoid Arthritis (RA)

Description:

Patients receiving tofacitinib from the Corrona RA Registry from November 2012 onward